Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1181-1200 of 3,900 trials

Vitiligo Treatment: Targeting TYK2 Responses

We are exploring a new treatment aimed at improving skin color in people with vitiligo. This study will help us understand if targeting specific responses can be beneficial.

Vitiligo>2 yearsEfficacy phase (II)Dermatology

Urothelial Cancer: Nivolumab with Relatlimab

We are studying a combination of nivolumab and relatlimab as a pre-surgery treatment for muscle-invasive bladder cancer. The goal is to see if this approach is effective and safe compared to nivolumab alone.

Muscle-Invasive Bladder CancerEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncologyUrology

Acute Myeloid Leukemia: Decitabine and Venetoclax with ATRA

We are studying whether adding all-trans retinoic acid to a treatment regimen helps patients with acute myeloid leukemia who cannot receive standard chemotherapy. The goal is to see if this combination improves survival and treatment response.

Acute Myeloid Leukemia>2 yearsConfirmation phase (III)11-15 visitsStandard MedicinesHematologyOncology

Penile Rehabilitation After Prostate Cancer Surgery: PEHAB II

We are studying two approaches to help men regain erections after nerve-sparing prostate surgery. The goal is to see which method leads to better sexual function and quality of life.

Prostate Cancer>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesPartially RemoteUrology

Castration-Resistant Prostate Cancer: Darolutamide with Radiation Therapy

We are studying whether adding stereotactic radiation therapy to darolutamide helps patients with castration-resistant prostate cancer and a few metastases live longer without disease progression. We will also evaluate the treatment's safety and impact on quality of life.

Castration-Resistant Prostate Cancer>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboInvestigational MedicinesOncologyUrology

Advanced Prostate Cancer: 225Ac-PSMA-Trillium Study

We are testing a new treatment for men with advanced metastatic castration-resistant prostate cancer. This study aims to see how well it works and its safety in humans.

Castration-Resistant Prostate Cancer>2 yearsSafety phase (I)Oncology

Statin Intolerance: Personalized Treatment Study

We are exploring whether personalized treatment plans can help people who struggle with statin medications. The goal is to improve their cholesterol management while minimizing side effects.

High Cardiovascular RiskStatin Intolerance6-12 monthsMonitoring phase (IV)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Hip Replacement Surgery: Shorter Blood Thinner Duration

We are studying whether a shorter course of blood-thinning medication after hip replacement surgery is as effective as the standard duration in preventing blood clots. This trial aims to improve recovery and safety for patients.

Hip Osteoarthritis3-6 monthsConfirmation phase (III)Standard MedicinesHematologyOrthopedics and Traumatology

Lung Cancer Treatment: Entrectinib vs. Crizotinib

We are comparing the effectiveness and safety of two medications for patients with advanced non-small cell lung cancer that has a specific genetic change. This study includes individuals with and without brain metastases.

Non-small Cell Lung Cancer>2 yearsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Hip Replacement: PENG Block vs. Lumbar Plexus Block

We are comparing two anesthesia methods for hip replacement surgery to see which one provides better pain relief and helps patients recover faster. We're also looking at hospital stay length and any side effects.

Total Hip Replacement1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesOrthopedics and TraumatologyOtolaryngology

Acute Myeloid Leukemia: Venetoclax Treatment Study

We are studying whether adding venetoclax to standard chemotherapy helps adults with newly diagnosed acute myeloid leukemia live longer and achieve better treatment results. This trial compares venetoclax to a placebo to assess its impact on patient outcomes.

Acute Myeloid Leukemia6-12 monthsConfirmation phase (III)Standard MedicinesHematology

Moderate Acne: Oral Isotretinoin vs. Standard Care

We are comparing a new oral medication to standard treatments for moderate acne in patients with skin of color. Our goal is to see if this new approach improves acne severity and quality of life.

Acne6-12 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesDermatology

Heart Blood Flow Measurement: SYN2 PET Imaging

We are testing a new imaging method to measure blood flow in the heart for patients suspected of having coronary artery disease. The study aims to ensure this method is accurate and safe for use.

Coronary Artery Disease1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCardiologyInternal Medicine

Basal Cell Carcinomas: Patidegib Gel 2%

We are studying a new gel for adults with Gorlin syndrome to see if it helps prevent basal cell carcinomas on the face. The trial will also check how safe and tolerable the gel is for patients.

Gorlin Syndrome1-2 yearsConfirmation phase (III)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteDermatologyHematology

Advanced Solid Tumors: MDNA11 and Pembrolizumab Study

We are investigating the safety and effectiveness of MDNA11, given alone or with pembrolizumab, in patients with advanced solid tumors. This study aims to find the best dose and understand how the treatment works.

Solid TumorSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Myasthenia Gravis: NMD670 Treatment Study

We are testing different doses of NMD670 in adults with Myasthenia Gravis to see if it improves muscle strength. This study will help us understand how effective the treatment is compared to a placebo.

Myasthenia Gravis≤3 monthsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Multiple Sclerosis: Disodium Cromoglycate Treatment

We are studying whether oral disodium cromoglycate can help reduce fatigue and urinary problems in people with multiple sclerosis. The trial will also assess its safety and impact on quality of life.

Multiple SclerosisEfficacy phase (II)Standard MedicinesInternal MedicineNeurology

Atrial Fibrillation: Apixaban vs. Warfarin in Dialysis Patients

We are comparing the safety and effectiveness of apixaban and warfarin for patients with atrial fibrillation on peritoneal dialysis. The study focuses on bleeding risks and the prevention of strokes and other serious health events.

Chronic Ambulatory Peritoneal DialysisConfirmation phase (III)No PlaceboStandard MedicinesCardiologyNephrology

Ulcerative Colitis: GRT-001 Treatment Study

We are evaluating a new treatment for ulcerative colitis in healthy volunteers and patients. The study aims to understand its safety and how it works in the body.

Ulcerative Colitis>2 yearsSafety phase (I)GastroenterologyInternal Medicine

Advanced Breast and Gastric Cancers: Disitamab Vedotin with Tucatinib

We are studying a new combination of disitamab vedotin and tucatinib for patients with advanced breast and gastric cancers. The goal is to find the best dose and evaluate its safety and effectiveness.

HER2 Positive Breast CancerOesophageal AdenocarcinomaGastric Cancer1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology